首页> 外国专利> PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF OBESITY COMPRISING LICARIN A OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS AN EFFECTIVE COMPONENT

PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF OBESITY COMPRISING LICARIN A OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS AN EFFECTIVE COMPONENT

机译：预防或治疗肥胖症的药物组合物，其中包含利卡林A或其有效盐类作为有效成分

页面导航

摘要
著录项
相似文献

摘要

The present invention relates to a pharmaceutical composition for preventing or treating obesity containing as an active ingredient licarin A (LA) or a pharmaceutically acceptable salt thereof, and more particularly to a pharmaceutical composition for preventing or treating obesity, Mesenchymal stem cells (MSCs) by browning of adipocytes showing phenotypes such as the production of multilocular lipid droplets, the increase of intracellular mitochondrial content and the number of copies, and the increase of expression of UCP1 (uncoupling protein 1) the present invention relates to a pharmaceutical composition for preventing or treating obesity which can induce differentiation of brown adipocytes or beige adipocytes of white adipocytes into stem cells or white adipocytes. The lyticin A or a pharmaceutically acceptable salt thereof according to the present invention can be applied to a medicine for the treatment of metabolic diseases such as obesity by effectively differentiating white adipocytes into brown or beige adipocytes through browning , And the pharmaceutical industry.

机译：本发明涉及含有利卡林A（LA）或其药学上可接受的盐作为有效成分的用于预防或治疗肥胖的药物组合物，更具体地说，涉及通过以下方式预防或治疗肥胖的间充质干细胞（MSC）的药物组合物：本发明涉及显示表型的脂肪细胞的褐变，例如多眼脂质液滴的产生，细胞内线粒体含量和拷贝数的增加以及 UCP1 （解偶联蛋白1）的表达的增加。用于预防或治疗肥胖的药物组合物，其可以诱导白色脂肪细胞的褐色脂肪细胞或米色脂肪细胞分化为干细胞或白色脂肪细胞。通过使褐变有效地将白色脂肪细胞分化为褐色或米色的脂肪细胞，本发明的溶菌素A或其药学上可接受的盐可以应用于肥胖症等代谢疾病的治疗，以及医药工业。 展开▼

著录项

公开/公告号KR101958236B1

专利类型

公开/公告日2019-03-14

原文格式PDF

申请/专利权人 순천향대학교 산학협력단;
展开▼

申请/专利号KR20170101654

发明设计人 김용식;임란 칸 모함마드;윤다현;
展开▼

申请日2017-08-10

分类号A61K31/343;A23L33/10;A61K8/49;A61Q19/06;

国家 KR

入库时间 2022-08-21 11:48:58

相似文献

专利

外文文献

中文文献

1. 包含山茶树提取物作为有效成分的用于预防及治疗病毒感染的药物组合物 [P] . 中国专利： CN113993533A . 2022-01-28

2. 抑制YAP-TEAD结合的化合物和包含其为有效成分的癌的预防或治疗用药物组合物 [P] . 中国专利： CN112996781A . 2021-06-18

3. PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF OBESITY COMPRISING LICARIN A OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS AN EFFECTIVE COMPONENT [P] . 韩国专利： KR20190017201A . 2019-02-20

机译：预防或治疗肥胖症的药物组合物，其中包含利卡林A或其有效盐类作为有效成分

4. PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF OBESITY COMPRISING MEDICARPIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS AN EFFECTIVE COMPONENT [P] . 韩国专利： KR101921735B1 . 2018-11-23

机译：预防或治疗肥胖的药物组合物，其中包括麦地卡因或可药用盐作为有效成分

5. PHARMACEUTICAL COMPOSITION FOR TREATMENT OF OBESITY COMPRISING DELPHINIDIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS AN EFFECTIVE COMPONENT [P] . 韩国专利： KR102022120B1 . 2019-09-18

机译：作为有效成分治疗包含德尔菲丁或药学上可接受的盐的肥胖症的药物组合物

1. Preclinical Evaluation of Pharmaceutical Compositions and Their Components for Urinary Health [J] . Francesco De Seta, Jonathan Wayne Lowery, Oladipupo Ogunbekun OMS II, 妇产科期刊（英文） . 2020,第001期

2. Screening of an Effective Degrading Strain for Treatment of Antibiotic Pharmaceutical Wastewater and Determination of Its Biological Properties [J] . Junfeng WANG, Pingping WANG 农业生物技术：英文版 . 2015,第002期

3. Screening Research of Pharmaceutical Compositions Based on Succinic Acid, Ascorbic Acid and Rutin [J] . Mariya Leleka, Olha Zalis＇ka, Galyna Kozyr 药剂与药理学：英文版 . 2016,第009期

4. NUTRACEUTICAL AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS [J] . Soap Perfumery and Cosmetics group Soap, Perfumery and Cosmetics . 2015,第7期

5. COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING PEPTIDES, USES AND TREATMENT PROCESSES [J] . Soap Perfumery and Cosmetics Group Soap, Perfumery and Cosmetics . 2010,第12期

6. Garlic oil and DDB, comprised in a pharmaceutical composition for the treatment of patients with viral hepatitis, prevents acute liver injuries potentiated by glutathione deficiency in rats. [J] . Park EY, Ki SH, Ko MS, Chemico-biological interactions . 2005,第1a2期

7. Pollution prevention and waste treatment in chemical synthesis processes for pharmaceutical industry [C] . I.Kabdasli, M.Gurel, O.Tunay International specialised conference on chemical process industries and environmental management . 1999

8. Rational Design of Pharmaceutical Salt Formulations by Understanding the Mechanism of Disproportionation [D] . Patel, Mitulkumar A. 2018

9. Vaccine for preventing or treating T-cell mediated pathology; comprises an effective amount of a T-lymphocyte receptor and a pharmaceutical medium; application in rheumatoid arthritis multiple sclerosis therapy diagnosis prevention [O] . -1

10. Year-book of Pharmacy, comprising abstracts of papers relating to Pharmacie, Materia medica, and Chemistry contributed to British and foreign Journals with the Transactions of the British Pharmaceutical Conference at the twelfth annual meeding held in Bristol, August 1875. London: J. A. Amrchill. Proceedings of the American Pharmaceutical Association at the twenty-third annual meeding, held in Boston, Mass., September 1875. Philadelphia: Sherman Co. [O] . F. Elsner 1876

1. Are Pharmaceutical Treatments or Psychological Approaches a More Effective Way of Treating Depression? [J] . Ruochen Wu . 临床护理研究 . 2020,第004期

2. Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents [J] . Hiroyasu Sakai ,Yohei Shirakami ,Masahito Shimizu . 世界胃肠病学杂志：英文版 . 2016,第1期

3. 二磷酸盐类药物预防和治疗骨质疏松的研究进展 [C] . Wei Guojun ,魏国俊 ,Ding Yufen . 第六届全国中西医结合骨科微创学术年会 . 2016

4. 黄荆子抗肿瘤有效部位EVn50及有效成分VBE-1、VBE-2生物转化、药物动力学比较研究 [A] . 李妍岚 . 2009